Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic β-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Wang, Lingshu ^a   Song, Jun ^a   Wang, Chuan ^a   Lin, Peng ^a   Liang, Kai ^a   Sun, Yu ^a   He, Tianyi ^a   Li, Wenjuan ^a   Zhao, Ruxing ^a   Qin, Jun ^a   Lu, Yiran ^a   Liu, Jinbo ^a   Liu, Fuqiang ^a   Hou, Xinguo ^a   Chen, Li ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETATROPHIN; C PEPTIDE; HORMONE; INSULIN; IRISIN; UNCLASSIFIED DRUG; FIBRONECTIN; FNDC5 PROTEIN, HUMAN; LIPASIN PROTEIN, HUMAN; PEPTIDE HORMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CELL FUNCTION; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; BLOOD; CROSS-SECTIONAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

C-PEPTIDE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRONECTINS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PEPTIDE HORMONES;

EID: 84948845304     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/2616539     Document Type: Article

References (28)

1. H. Lickert, "Betatrophin fuels β cell proliferation: first step toward regenerative therapy?" Cell Metabolism, vol. 18, no. 1, pp. 5-6, 2013.
2. F. Sanchis-Gomar and C. Perez-Quilis, "The p38-PGC-1α- irisin-betatrophin axis: exploring new pathways in insulin resistance," Adipocyte, vol. 3, no. 1, pp. 67-68, 2014.
3. G. Ren, J. Y. Kim, and C. M. Smas, "Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism," American Journal of Physiology-Endocrinology and Metabolism, vol. 303, no. 3, pp. E334-E351, 2012.
4. R. Zhang, "Lipasin, a novel nutritionally-regulated liverenriched factor that regulates serum triglyceride levels," Biochemical and Biophysical Research Communications, vol. 424, no. 4, pp. 786-792, 2012.
5. P. Yi, J.-S. Park, and D. A. Melton, "Betatrophin: a hormone that controls pancreatic β cell proliferation," Cell, vol. 153, no. 4, pp. 747-758, 2013.
6. Y. Wang, F. Quagliarini, È. Gusaroèa et al., "Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 40, pp. 16109-16114, 2013.
7. V. Gusarova, C. A. Alexa, E. Na et al., "ANGPTL8/betatrophin does not control pancreatic beta cell expansion," Cell, vol. 159, no. 3, pp. 691-696, 2014.
8. P. Boström, J. Wu, M. P. Jedrychowski et al., "A PGC1-α- dependent myokine that drives brown-fat-like development of white fat and thermogenesis," Nature, vol. 481, no. 7382, pp. 463-468, 2012.
9. M. Yang, P. Chen, H. Jin et al., "Circulating levels of irisin in middle-aged first-degree relatives of type 2 diabetes mellitus-correlation with pancreatic beta-cell function," Diabetology & Metabolic Syndrome, vol. 6, no. 1, p. 133, 2014.
10. Y. Zhang, R. Li, Y. Meng et al., "Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERKMAP kinase signaling," Diabetes, vol. 63, no. 2, pp. 514-525, 2014.
11. J. P. Palmer, G. A. Fleming, C. J. Greenbaum et al., "Cpeptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001," Diabetes, vol. 53, no. 1, pp. 250-264, 2004.
12. K. G. M. M. Alberti and P. Z. Zimmet, "Definition, diagnosis and classification of diabetesmellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation," Diabetic Medicine, vol. 15, no. 7, pp. 539-553, 1998.
13. J. C. Levy, D. R. Matthews, and M. P. Hermans, "Correct homeostasis model assessment (HOMA) evaluation uses the computer program," Diabetes Care, vol. 21, no. 12, pp. 2191-2192, 1998.
14. L. Zhao, J. Ma, S. Wang, and Y. Xie, "Relationship between β-cell function, metabolic control, and microvascular complications in type 2 diabetesmellitus," Diabetes Technology & Therapeutics, vol. 17, no. 1, pp. 29-34, 2015.
15. H. Hu, W. Sun, S. Yu et al., "Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients," Diabetes Care, vol. 37, no. 10, pp. 2718-2722, 2014.
16. D. Espes, M. Martinell, and P.-O. Carlsson, "Increased circulating betatrophin concentrations in patients with type 2 diabetes," International Journal of Endocrinology, vol. 2014, Article ID 323407, 6 pages, 2014.
17. X. Chen, P. Lu, W. He et al., "Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance," The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 1, pp. E96-E100, 2015.
18. A. Fenzl, B. K. Itariu, L. Kosi et al., "Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals," Diabetologia, vol. 57, no. 6, pp. 1204-1208, 2014.
19. Y. Jiao, J. le Lay, M. Yu, A. Naji, and K. H. Kaestner, "Elevated mouse hepatic betatrophin expression does not increase human beta-cell replication in the transplant setting," Diabetes, vol. 63, no. 4, pp. 1283-1288, 2014.
20. A. F. Stewart, "Betatrophin versus bitter-trophin and the elephant in the room: time for a new normal in β-cell regeneration research," Diabetes, vol. 63, no. 4, pp. 1198-1199, 2014.
21. D. P. Kelly, "Medicine: Irisin, light my fire," Science, vol. 335, no. 6077, pp. 42-43, 2012.
22. C. Wang, L. Wang, W. Li et al., "Irisin has no effect on lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes," Endocrine, vol. 49, no. 1, pp. 90-96, 2015.
23. K. H. Park, L. Zaichenko, M. Brinkoetter et al., "Circulating irisin in relation to insulin resistance and the metabolic syndrome," Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 12, pp. 4899-4907, 2013.
24. C. Zhang, Z. Ding, G. Lv, J. Li, P. Zhou, and J. Zhang, "Lower irisin level in patients with type 2 diabetes mellitus: a casecontrol study and meta-analysis," Journal of Diabetes, 2014.
25. J. M. Moreno-Navarrete, F. Ortega, M. Serrano et al., "Irisin is expressed and produced by humanmuscle and adipose tissue in association with obesity and insulin resistance," The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 4, pp. E769-E778, 2013.
26. N. M. Al-Daghri, K. M. Alkharfy, S. Rahman et al., "Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects," European Journal of Clinical Investigation, vol. 44, no. 2, pp. 119-124, 2014.
27. B. Palacios-González, F. Vadillo-Ortega, E. Polo-Oteyza et al., "Irisin levels before and after physical activity among schoolage children with different BMI: a direct relation with leptin," Obesity, vol. 23, no. 4, pp. 729-732, 2015.
28. A. Rodríguez, S. Becerril, L. Méndez-Giménez et al., "Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice," International Journal of Obesity, vol. 39, no. 3, pp. 397-407, 2015.